<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="868">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05149859</url>
  </required_header>
  <id_info>
    <org_study_id>2022-3743, 22144</org_study_id>
    <nct_id>NCT05149859</nct_id>
  </id_info>
  <brief_title>Compuls-BED-Severity</brief_title>
  <official_title>Reconsidering Severity Classification for Binge Eating Disorder (BED): the Role of Impulsivity, Compulsivity and Co-occurring Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut universitaire de cardiologie et de pneumologie de Québec, University Laval</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre d'expertise Poids, Image et Alimentation (CEPIA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Binge Eating Disorder (BED) has been fairly recently introduced into the Diagnostic and&#xD;
           Statistical Manual 5 psychiatric classification and its severity criteria are still not&#xD;
           well established.&#xD;
&#xD;
        -  Moreover, it remains unclear whether BED is associated with greater metabolic severity&#xD;
           or more somatic comorbidities, especially in obesity.&#xD;
&#xD;
        -  Improved BED severity staging could lead to a better definition of management strategies&#xD;
           and , therefore, facilitate screening and care.&#xD;
&#xD;
      The investigators' hypothesis is that an improved assessment of the impulsivity-compulsivity&#xD;
      spectrum, emotional regulation, attentional impairment and somatic or psychiatric&#xD;
      comorbidities will result in a better distinction between the severe form of BED (e.g.,&#xD;
      highly impulsive and somatically complicated) from milder form (e.g., more compulsive and&#xD;
      less somatically complicated).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Physical and psychological comorbidities</measure>
    <time_frame>Inclusion</time_frame>
    <description>Number of current associated comorbidities to patient with and without BED</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Binge Eating Scale score</measure>
    <time_frame>Inclusion</time_frame>
    <description>To assess binge eating severity based on the 16-item scale developed by Gormally et al in 1982</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index in kg.m-2</measure>
    <time_frame>Inclusion</time_frame>
    <description>[Anthropometric markers] weight and height will be combined to report BMI in kg/m^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of fat mass in %</measure>
    <time_frame>Inclusion</time_frame>
    <description>[Anthropometric markers] Based on impedance data, percentage fat mass will be reported when available</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist and hip circumferences in cm</measure>
    <time_frame>Inclusion</time_frame>
    <description>[Anthropometric markers] Waist, hip circumference and Waist-hip ratio will be reported in cm when available</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides in mmol/L</measure>
    <time_frame>Inclusion</time_frame>
    <description>Routine clinical biological markers; part of lipidic profile (when available)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol HDL and LDL in mmol/L</measure>
    <time_frame>Inclusion</time_frame>
    <description>Routine clinical biological markers; part of lipidic profile (when available)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting blood glucose in mmol/L</measure>
    <time_frame>Inclusion</time_frame>
    <description>Routine clinical biological markers, when available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated hemoglobin (HbA1C) in %</measure>
    <time_frame>Inclusion</time_frame>
    <description>Routine clinical biological markers, when available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin in pmol/L</measure>
    <time_frame>Inclusion</time_frame>
    <description>Routine clinical biological markers, when available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visceral Adiposity Index</measure>
    <time_frame>Inclusion</time_frame>
    <description>The Visceral Adiposity Index (VAI) is a sex-specific mathematical index, based on Waist Circumference (WC), Body Mass Index (BMI), triglycerides (TG) and HDL cholesterol (HDL) levels, indirectly expressing visceral adipose function and insulin sensitivity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPPS-P Impulsive Behavior Scale short version, S-UPPS-P</measure>
    <time_frame>Inclusion</time_frame>
    <description>To assess the Impulsivity-compulsivity spectrum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obsessive-Compulsive Inventory-Revised, OCI-R</measure>
    <time_frame>Inclusion</time_frame>
    <description>To assess the Impulsivity-compulsivity spectrum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stop Signal Task</measure>
    <time_frame>Inclusion</time_frame>
    <description>To assess the Impulsivity-compulsivity spectrum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difficulties in emotion regulation scale short form, DERS</measure>
    <time_frame>Inclusion</time_frame>
    <description>To assess the emotion regulation spectrum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotional Go / No-Go Task</measure>
    <time_frame>Inclusion</time_frame>
    <description>To assess the emotion regulation spectrum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adult Attention Deficit Hyperactivity Disorder Self-Report Scale, ASRS</measure>
    <time_frame>Inclusion</time_frame>
    <description>To assess attentional functions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Integrated Visual and Auditory Continuous Performance Test, IVA-CPT</measure>
    <time_frame>Inclusion</time_frame>
    <description>To assess attentional functions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General Anxiety Disorder (GAD)-7</measure>
    <time_frame>Inclusion</time_frame>
    <description>To assess anxiety disorders risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Health Questionnaire (PHQ)-9</measure>
    <time_frame>Inclusion</time_frame>
    <description>To assess depression disorder risk</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Binge-Eating Disorder</condition>
  <arm_group>
    <arm_group_label>BED+ : Participants with obesity and binge eating disorder</arm_group_label>
    <description>Obesity is define by a BMI ≥ 30 kg.m-2 Binge eating disorder is defined by Binge Eating Disorder Screener (BEDS)-7 positive score and a Binge Eating Scale score &gt;16</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BED-: Participants with obesity but without binge eating disorder</arm_group_label>
    <description>Obesity is define by a BMI ≥ 30 kg.m-2 Binge eating disorder is defined by Binge Eating Disorder Screener (BEDS)-7 negative score and a Binge Eating Scale score &lt; 12</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational</intervention_name>
    <description>(no intervention)</description>
    <arm_group_label>BED+ : Participants with obesity and binge eating disorder</arm_group_label>
    <arm_group_label>BED-: Participants with obesity but without binge eating disorder</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited from 2 sites: 1) the Institut Universitaire de Cardiologie et&#xD;
        Pneumologie de Québec (IUCPQ; pre-bariatric surgery consultation and obesity care&#xD;
        consultation); 2) the Centre d'Expertise Poids, Image et Alimentation (CEPIA), a clinic of&#xD;
        the Institute of Nutrition and Functional Foods of Laval University (eatinig disorders&#xD;
        consultation). The pre-selection of participants will be done using available data and&#xD;
        screening tests deployed through the management frameworks already in place at the two&#xD;
        sites. If needed, patients will be recruited by advertisement.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  men or women aged 1&#xD;
&#xD;
          -  participants eligible for bariatric surgery (BMI&gt;40, or BMI&gt;35 with severe&#xD;
             comorbidities)&#xD;
&#xD;
          -  participants scheduled for medical evaluation and treatment of obesity at the IUCPQ&#xD;
             Obesity Clinic (BMI≥30)&#xD;
&#xD;
          -  participants scheduled for evaluation and treatment of BED at the CEPIA with obesity&#xD;
             (BMI≥30)&#xD;
&#xD;
          -  for the group with BED: positive BEDS-7 screen and Binge Eating Scale score &gt;16;&#xD;
&#xD;
          -  for the control group: have a negative BEDS-7 screen and Binge Eating Scale score&lt;12&#xD;
&#xD;
          -  be fluent in French and able to consent.&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
          -  participants with severe neurological disorder and/or major neurocognitive deficits;&#xD;
&#xD;
          -  participants with previous bariatric surgery or with introduction or change of&#xD;
             anti-obesity medication (liraglutide or naltrexone/bupropion) in the previous 3&#xD;
             months;&#xD;
&#xD;
          -  participants who cannot read and/or understand French;&#xD;
&#xD;
          -  participants under guardianship or curatorship;&#xD;
&#xD;
          -  participants already included in a study with a conflict of interest with this study;&#xD;
&#xD;
          -  inability to use a computer or iPad;&#xD;
&#xD;
          -  inability to access an Internet connection or to visit one of the inclusion sites.&#xD;
&#xD;
        Secondary exclusion criteria:&#xD;
&#xD;
          -  participants with a discordance between BEDS-7 (positive) and Binge Eating Scale&#xD;
             (score ≤ 16) results found secondarily&#xD;
&#xD;
          -  participants who did not participate in part of the assessments (e.g.,&#xD;
             self-questionnaires or neurocognitive tests) and participants with a rate of missing&#xD;
             data&gt;10%.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvain Iceta</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut universitaire de cardiologie et de pneumologie de Québec, University Laval</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sylvain Iceta, MD, PhD</last_name>
    <phone>+1 (418) 656-8711</phone>
    <phone_ext>4565</phone_ext>
    <email>equipe.iceta@criucpq.ulaval.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pelletier Melissa</last_name>
    <phone>+1 (418) 656-8711</phone>
    <phone_ext>2136</phone_ext>
    <email>equipe.iceta@criucpq.ulaval.ca</email>
  </overall_contact_backup>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 19, 2021</study_first_submitted>
  <study_first_submitted_qc>December 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>December 7, 2021</last_update_submitted>
  <last_update_submitted_qc>December 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Binge-Eating Disorder</keyword>
  <keyword>Impulsivity</keyword>
  <keyword>Obesity</keyword>
  <keyword>Attention</keyword>
  <keyword>Emotional regulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bulimia</mesh_term>
    <mesh_term>Feeding and Eating Disorders</mesh_term>
    <mesh_term>Binge-Eating Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

